238 related articles for article (PubMed ID: 26302239)
1. On the restricted mean survival time curve in survival analysis.
Zhao L; Claggett B; Tian L; Uno H; Pfeffer MA; Solomon SD; Trippa L; Wei LJ
Biometrics; 2016 Mar; 72(1):215-21. PubMed ID: 26302239
[TBL] [Abstract][Full Text] [Related]
2. [Application of restricted mean survival time in clinical follow-up study].
Yang ZJ; Lyu JJ; Hou YW; Chen Z
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
[TBL] [Abstract][Full Text] [Related]
3. On the empirical choice of the time window for restricted mean survival time.
Tian L; Jin H; Uno H; Lu Y; Huang B; Anderson KM; Wei LJ
Biometrics; 2020 Dec; 76(4):1157-1166. PubMed ID: 32061098
[TBL] [Abstract][Full Text] [Related]
4. Adjusting for covariates in analysis based on restricted mean survival times.
Zhong Y; Zhao O; Zhang B; Yao B
Pharm Stat; 2022 Jan; 21(1):38-54. PubMed ID: 34231308
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
6. Dynamic RMST curves for survival analysis in clinical trials.
Liao JJZ; Liu GF; Wu WC
BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
[TBL] [Abstract][Full Text] [Related]
7. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
Kloecker DE; Davies MJ; Khunti K; Zaccardi F
Ann Intern Med; 2020 Apr; 172(8):541-552. PubMed ID: 32203984
[TBL] [Abstract][Full Text] [Related]
8. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
9. Omnibus test for restricted mean survival time based on influence function.
Gu J; Fan Y; Yin G
Stat Methods Med Res; 2023 Jun; 32(6):1082-1099. PubMed ID: 37015346
[TBL] [Abstract][Full Text] [Related]
10. Analysis of restricted mean survival time for length-biased data.
Lee CH; Ning J; Shen Y
Biometrics; 2018 Jun; 74(2):575-583. PubMed ID: 28886217
[TBL] [Abstract][Full Text] [Related]
11. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
[TBL] [Abstract][Full Text] [Related]
12. Restricted mean survival time over 15 years for patients starting renal replacement therapy.
Couchoud C; Dantony E; Elsensohn MH; Villar E; Vigneau C; Moranne O; Rabilloud M; Ecochard R
Nephrol Dial Transplant; 2017 Apr; 32(suppl_2):ii60-ii67. PubMed ID: 28057870
[TBL] [Abstract][Full Text] [Related]
13. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
Abulizi X; Ribaudo HJ; Flandre P
J Acquir Immune Defic Syndr; 2019 May; 81(1):44-51. PubMed ID: 30789450
[TBL] [Abstract][Full Text] [Related]
14. Restricted mean survival time as a summary measure of time-to-event outcome.
Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
[TBL] [Abstract][Full Text] [Related]
15. An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use.
Calkins KL; Canan CE; Moore RD; Lesko CR; Lau B
BMC Med Res Methodol; 2018 Mar; 18(1):27. PubMed ID: 29523081
[TBL] [Abstract][Full Text] [Related]
16. Dynamic prediction and analysis based on restricted mean survival time in survival analysis with nonproportional hazards.
Yang Z; Wu H; Hou Y; Yuan H; Chen Z
Comput Methods Programs Biomed; 2021 Aug; 207():106155. PubMed ID: 34038865
[TBL] [Abstract][Full Text] [Related]
17. [Interpretation and Application of Restricted Mean Survival Time].
Hasegawa T
Gan To Kagaku Ryoho; 2022 Apr; 49(4):389-396. PubMed ID: 35444119
[TBL] [Abstract][Full Text] [Related]
18. Bayesian nonparametric analysis of restricted mean survival time.
Zhang C; Yin G
Biometrics; 2023 Jun; 79(2):1383-1396. PubMed ID: 35034347
[TBL] [Abstract][Full Text] [Related]
19. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
Monnickendam G; Zhu M; McKendrick J; Su Y
Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
[TBL] [Abstract][Full Text] [Related]
20. Noninferiority hypotheses and choice of noninferiority margin.
Ng TH
Stat Med; 2008 Nov; 27(26):5392-406. PubMed ID: 18680173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
